Resultats globals: 1 registres trobats en 0.03 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
10 p, 685.7 KB Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia : the phase 2 CAPTIVATE study / Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ; Tam, Constantine S. (Monash University) ; Grigg, Andrew (Austin Hospital) ; Scarfò, Lydia (Università Vita Salute San Raffaele) ; Kipps, Thomas J. (University of California. Moores Cancer Center) ; Srinivasan, Srimathi (Janssen Research & Development) ; Mali, Raghuveer Singh (Pharmacyclics LLC. an AbbVie Company) ; Zhou, Cathy (Pharmacyclics LLC. an AbbVie Company) ; Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ; Szafer Glusman, Edith (Pharmacyclics LLC. an AbbVie Company) ; Choi, Michael (University of California)
We evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax in the minimal residual disease (MRD) cohort of the CAPTIVATE study (NCT02910583). [...]
2023 - 10.1182/bloodadvances.2023010236
Blood advances, Vol. 7 Núm. 18 (26 2023) , p. 5294-5309  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.